Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
207 participants
INTERVENTIONAL
2013-02-27
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
NCT01549275
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421
Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients
NCT02587793
Transient Elastography in Hepatectomy for Hepatocellular Carcinoma
NCT01441453
Development of a New Method for Liver Stiffness Measurement Using FibroScan
NCT06519331
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TACE
Fibroscan
Systemic Therapy
Fibroscan
Surgery
Fibroscan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fibroscan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery
1. For TACE cohort, patients undergoing first cycle TACE are eligible.
2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
3. For surgery cohort, patient undergoing surgery are eligible.
* Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed
* Child's A to Child's C liver function
Exclusion Criteria
* Poorly controlled ascites
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CCTU
Comprehensive Cancer Trials Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen Lam Chan, FHKCP
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCC033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.